ESTRO 38 Abstract book

S768 ESTRO 38

3 fractions. Immobilization included a vacuum pillow in all and abdominal compression in 5 patients. Treatment planning was based on contrast-enhanced 4D-CT using an ITV concept with a PTV margin of 6 mm. Daily image guidance was performed with CBCT using fiducial markers or lipiodol enhancement after TACE. Results Results : Median interval between SBRT and OLT was 6 months (range 1-8 months). Median follow-up from SBRT was 24 months (range 7-79). All patients remained locally and distantly controlled until OLT. In 5/6 patients and 6/7 lesions no residual HCC (pathologic complete response) was found in the explanted liver. The only patient with residual disease had been treated with SBRT only (no TACE) and received OLT early (1 month) after SBRT. No acute toxicity from SBRT was observed, except deterioration of liver function in the CP C patient salvaged by OLT. One patient died shortly after OLT due to postoperative complications and one due to distant failure 9 months after OLT, resulting in a 2yr-OS rate of 66%. Conclusion Conclusion : SBRT with or without TACE is a locally effective and well-tolerated bridging treatment for HCC patients listed for orthotopic liver transplantation. EP-1413 Correlation between N-L Ratio,P-L Ratio and Survival in patients with LAPC: A new prognostic factor? P. Trecca 1 , M. Fiore 1 , C. Greco 1 , E. Ippolito 1 , R.M. D'Angelillo 1 , L. Trodella 1 , S. Ramella 1 1 Campus-Bio Medico University, Radiotherapy Unit, Rome, Italy Purpose or Objective The aim of the study was to investigate the role of inflammatory markers such as neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) in predicting the prognosis of patients with locally advanced pancreatic cancer (LAPC) treated by radiochemotherapy (RCT) Material and Methods Fifty-two patients (F:30; M:22; median age 64 years, range 40-75 yrs) with histologically proven pancreatic ductal adenocarcinoma enrolled in a prospective one-armed phase II study were evaluated. All patients were treated with gemcitabine-based RCT after an accurate pre- treatment staging. NLR and PLR were calculated from data collected within 14 days before the start of the concurrent RCT. We stratified population into groups according to the cut-off values: NLR<3 (n=30 pts), NLR ≥3 (n=22 pts), PLR<200 (n=38 pts), PLR ≥200 (n=14 pts). Survival data among subgroups classified by each factor were analyzed via the Kaplan–Meier curve and compared by the log-rank test. Results For NLR<3 and NLR≥3 groups, respectively, median OS were 17.7 months and 13 months (p=0.15), and median PFS were 12.4 months and 18.1 months (p=0.4). For PLR<200 and PLR≥200 groups, respectively, median OS were 21.5 months and 12.4 months (p<0.001), and median PFS were 20 months and 12.5 months (p=0.2). Conclusion These data suggest that high NLR and high PLR could predict worst OS and PFS. More studies with a large population may be useful in order to validate NLR and PLR as predicting markers for prognosis of patients with LAPC. EP-1414 SBRT for the treatment of hepatocellular carcinoma: a retrospective multicenter study N. Scher 1 , F.G. Riet 2 , G. Janoray 1 , K. Debbi 1 , S. Levy 1 , P. Louisot 1 , E. Chajon 2 , E. Salame 1 , I. Barillot 1 , R. De Crevoisier 2 , G. Calais 1 , S. Chapet 1 1 Hopital Bretonneau, Centre, Tours, France ; 2 Centre Eugene Marquis, Bretagne, Rennes, France

included and distributed to a panel of 8 radiation oncologists. Liver locations were segments II, IV (2) and VI (3). The cases show different difficulty: low acquisition contrast, previously treated with chemotherapy, inhomogeneous liver parenchyma or low SUV in PET/CT. The agreement was assessed using the kappa- statistic. Agreement interpretation was evaluated using Landis and Koch’s interpretation. The institutional review boards approved the study. Results The median GTV volume on MRI was 2,8 mL (0,7–16,1 mL), compared to 3mL on CT (0,6–8,6 mL) (p=0,07). The median GTV volume on PET was 6 mL (2,5-18mL), compared to 3mL on CT (0,6–8,6 mL) (p=0,15). Variance between observers in CT was minor that MRI and PET (5,75 vs 9 vs 19,9). The index of agreement was low (0,083) between CT and MRI in all patients.The index of agreement was low (kappa=0,005) between CT and PET in all patients. Conclusion In cases with well-defined tumor CT is more easy and reproductible. In cases with no defined tumor in CT we need other tools: MRI and/or PET/CT. The interobserver variability in target delineation in this study is noteworthy. Multi-institution consensus was necessary. EP-1412 Excellent pCR rate in patients with HCC after SBRT +/- TACE as bridging to liver transplantation S. Gerum 1 , C. Heinz 2 , C. Belka 3 , P.M. Paprottka 4 , J. Neumann 5 , E. De Toni 6 , M. Guba 7 , F. Roeder 8 1 Radiation Oncology- University of Munich LMU- Germany, Department of Radiation Oncology- University of Munich LMU- Germany, Munich, Germany ; 2 Radiation Oncology- University of Munich LMU- Physics, Department of Radiation Oncology- University of Munich LMU- Germany, Munich, Germany ; 3 Radiation Oncology- University of Munich LMU-, Department of Radiation Oncology- University of Munich LMU- Germany, Munich, Germany ; 4 Interventional Radiology- LMU, Department of interventional Radiology- LMU- University Hospital of Munich, Munich, Germany ; 5 Pathology- LMU, Department of Pathology- LMU- University Hospital of Munich- Germany, Munich, Germany ; 6 Gastroenterology, Department of Medicine II- Liver Center Munich- University Hospital- Munich- Germany., Munich, Germany ; 7 Visceral- Vascular- Transplantation Surgery, Department of General- Visceral- Vascular and Transplantation Surgery- Hospital of the LMU Munich- Germany, Munich, Germany ; 8 Radiation Oncology- University of Munich LMU-, Department of Radiation Oncology- LMU- University Hospital of Munich- Germany, Munich, Germany Purpose or Objective Background: To report histopathological response rate and overall outcome after stereotactic body radiotherapy (SBRT) +/-TACE (transarterial chemoembolisation) as bridging to orthotopic liver transplantation (OLT) in patients with hepatocellular carcinoma (HCC). Material and Methods Patients and methods : We retrospectively analyzed 6 patients with 7 HCC lesions, who had been listed for orthotopic liver transplantation and had received SBRT as bridging treatment. All patients fulfilled EASL criteria for diagnosis and Milan criteria for OLT eligibility. All patients were judged ineligible for other locally ablative treatments (except TACE) or surgical resection by multidisciplinary evaluation. 4 patients received SBRT within 6 weeks from TACE of the same lesion(s). Liver function was Child-Pugh class A in 3, B in 2 and C in 1 patient(s). Cause of underlying cirrhosis was toxic in 2, hepatitis viral infection in 2 and autoimmune in 2 patients. Dose and fractionation varied dependent on localisation, size, motion and liver function. 6/7 lesions were treated with 37.5 Gy prescribed to the surrounding 65% isodose in

Purpose or Objective